{
    "clinical_study": {
        "@rank": "50351", 
        "acronym": "MG4101", 
        "arm_group": {
            "arm_group_label": "MG4101", 
            "arm_group_type": "Active Comparator", 
            "description": "Ex vivo expanded allogeneic NK cell"
        }, 
        "brief_summary": {
            "textblock": "To see the safety and efficacy of injecting MG4101 as a secondary treatment after curative\n      liver resection on the patient with advanced HCC who has high risk of recurrence."
        }, 
        "brief_title": "to Evaluate the Efficacy and Safety of MG4101(Ex Vivo Expanded Allogeneic NK Cell)", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Hepatocellular Carcinoma", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Carcinoma, Hepatocellular"
            ]
        }, 
        "detailed_description": {
            "textblock": "To see the safety and efficacy of injecting MG4101(Ex vivo expanded allogeneic NK cell) as a\n      secondary treatment after curative liver resection on the patient with advanced HCC who has\n      high risk of recurrence."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Under the age of 20 to 69 years of age\n\n          2. Child-pugh class A\n\n          3. After curative liver resection, diagnosed hepatocellular carcinoma\n\n          4. Modified UICC staging : stage 3\n\n          5. the women who is childbearing age, agree to maintain adequate contraception measure\n             during clinical trial period.\n\n          6. Agreed to participate in this clinical trial, agree to  the subject person or legal\n             representative who agrees in writing\n\n        Exclusion Criteria:\n\n          1. Less than 20 years old, 70 years old or older\n\n          2. Metastasis of hepatocellular carcinoma with external parties surgery\n\n          3. who had Rupture of hepatocellular carcinoma (HCC)\n\n          4. Hepatocellular carcinoma treated with radiofrequency surgery therapeutics\n             (Radiofrequency ablation, RFA), the carotid artery chemical embolization\n             (Transarterial chemoembolization, TACE), underwent radiation therapy, such as topical\n             therapeutics\n\n          5. suspected serious infection\n\n          6. Who have severe cardiovascular disease (coronary artery disease requiring treatment,\n             heart failure, arrhythmias, myocardial infarction, etc.)\n\n          7. Pregnant, planning a pregnancy or breast-feeding women\n\n          8. Autoimmune Disease\n\n          9. Those who Latest within four weeks of administration of systemic steroids (However,\n             inhalation, intranasal corticosteroids and topical administration of corticosteroids\n             and short-time administration of a blood transfusion, if such reasons are excluded)\n\n         10. Latest within four weeks of taking immunosuppressive drugs such as Cyclosporine A\n\n         11. Within the last 5 years diagnosed with liver cancer and other malignancies\n\n         12. Investigator did not complete or the effectiveness or safety of pharmaceutical\n             products of this clinical trial evaluation for any medical condition that can\n             interfere with characters judged"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "69 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 8, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02008929", 
            "org_study_id": "HCC_ MG4101"
        }, 
        "intervention": {
            "arm_group_label": "MG4101", 
            "description": "Ex vivo expanded allogeneic NK cell", 
            "intervention_name": "MG4101", 
            "intervention_type": "Biological", 
            "other_name": "NK cell"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "NKCELL", 
        "lastchanged_date": "December 8, 2013", 
        "location": {
            "contact": {
                "email": "jw.joh@samsung.com", 
                "last_name": "Jae-Won Joh, MD., PhD", 
                "phone": "82-2-3410-3466"
            }, 
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of", 
                    "zip": "135-710"
                }, 
                "name": "Samsung Medical Center"
            }, 
            "investigator": [
                {
                    "last_name": "Jae-Won Joh, MD., PhD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Jong-man Kim, MD., PhD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Single Center, Open-label, Phase II Clinical Trial to Evaluate the Efficacy and Safety of MG4101(Ex Vivo Expanded Allogeneic NK Cell) in Hepatocellular Carcinoma After Curative Resection", 
        "overall_contact": {
            "email": "jw.joh@samsung.com", 
            "last_name": "Jae-Won Joh, MD., PhD", 
            "phone": "82-2-3410-3466"
        }, 
        "overall_contact_backup": {
            "email": "yura.choi@mediex.co.kr", 
            "last_name": "Yu-ra Choi", 
            "phone": "82-2-3482-7831"
        }, 
        "overall_official": {
            "affiliation": "Samsung Medical Center", 
            "last_name": "Jae-Won Joh, MD., PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "South Korea: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "As of Date for allocation to survival and recurrence of the incident or death from any cause is defined as. 1 year disease-free survival was calculated using Kaplan-Meier estimation and 95% confidence interval and median survival (median survival time) are presented.", 
            "measure": "Disease free survival, DFS", 
            "safety_issue": "Yes", 
            "time_frame": "Disease free survival for 1year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02008929"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Samsung Medical Center", 
            "investigator_full_name": "JAE WON JOH", 
            "investigator_title": "Clinical Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Basaline(V2) at each visit compared (V6, V8, V9, V10) with respect to variation in average by descriptive statistics (mean, standard deviation, median, minimum, maximum) and presented, in comparison to the group in order Paired t-test or the Wilcoxon's signed rank test for analysis.", 
                "measure": "Changes in tumor markers", 
                "safety_issue": "No", 
                "time_frame": "Changes in tumor markers. to be specific, alpha-fetoprotein(AFP), protein induced by vitamin K absence- II(PIVKA-II)"
            }, 
            {
                "description": "As of Date for allocation to survival, and the incident was defined as death from any cause.\n1 year overall survival was calculated using Kaplan-Meier estimation and 95% confidence interval and median survival (median survival time) are presented.", 
                "measure": "Overall survival, OS", 
                "safety_issue": "No", 
                "time_frame": "Overall survival, OS at the end point of clinical trial"
            }
        ], 
        "source": "Samsung Medical Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Samsung Medical Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}